Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
45.74
-1.25 (-2.66%)
Jan 17, 2025, 4:00 PM EST - Market closed
Cytokinetics Revenue
Cytokinetics had revenue of $463.00K in the quarter ending September 30, 2024, with 22.49% growth. This brings the company's revenue in the last twelve months to $3.22M, down -58.81% year-over-year. In the year 2023, Cytokinetics had annual revenue of $7.53M, down -92.04%.
Revenue (ttm)
$3.22M
Revenue Growth
-58.81%
P/S Ratio
n/a
Revenue / Employee
$7,610
Employees
423
Market Cap
5.40B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 7.53M | -87.06M | -92.04% |
Dec 31, 2022 | 94.59M | 24.16M | 34.30% |
Dec 31, 2021 | 70.43M | 14.60M | 26.15% |
Dec 31, 2020 | 55.83M | 28.96M | 107.79% |
Dec 31, 2019 | 26.87M | -4.63M | -14.71% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
CYTK News
- 7 days ago - Cytokinetics Announces 2025 Corporate Milestones and Vision 2030 - GlobeNewsWire
- 14 days ago - Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 17 days ago - Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewsWire
- 20 days ago - Cytokinetics Aligns For U.S. Launch Amid HCM Market Evolution - Seeking Alpha
- 4 weeks ago - Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy - GlobeNewsWire
- 4 weeks ago - Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China - GlobeNewsWire
- 6 weeks ago - Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Cytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction - GlobeNewsWire